Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,103 recruiting studies in this area right now.
By phase
- Not applicable9,481
- Phase 24,388
- Phase 12,656
- Phase 1/Phase 21,646
- Phase 31,390
- Phase 2/Phase 3282
- Phase 4260
Top conditions
- Breast Cancer1,192
- Prostate Cancer645
- Cancer633
- Colorectal Cancer480
- Lung Cancer415
- Ovarian Cancer336
- Multiple Myeloma327
- Pancreatic Cancer289
- Gastric Cancer283
- Acute Myeloid Leukemia281
- Hepatocellular Carcinoma256
- Solid Tumor245
- Advanced Solid Tumor236
- Head and Neck Cancer224
- Cervical Cancer223
- Endometrial Cancer206
- Advanced Solid Tumors198
- Esophageal Cancer189
Leading sponsors
- M.D. Anderson Cancer Center452
- Fudan University302
- National Cancer Institute (NCI)293
- Memorial Sloan Kettering Cancer Center291
- Sun Yat-sen University273
- Mayo Clinic237
- City of Hope Medical Center141
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences140
- AstraZeneca134
- Second Affiliated Hospital, Zhejiang University, School of Medicine128
Where studies are running
- California1,412
- Texas636
- Arizona514
- Florida429
- Alabama426
- New York407
- Massachusetts341
- Maryland332
- New Jersey269
- Pennsylvania234
Recruiting studies20,103 total
- NCT07365995RecruitingPhase 3
New drug for advanced prostate cancer vs. standard chemo
This trial tests a new drug called BNT324 against the standard chemotherapy docetaxel for men with advanced prostate cancer that has stopped responding to hormone therapy. It aims to see if the new treatment can help control the cancer better.
Santa Barbara, CaliforniaAges 18 years+ - NCT03197363Enrolling by invitation
Long-term study of adults living in Białystok
This study follows adults living in Białystok over time to learn about health and life patterns. If you’re invited to take part and agree, it may help researchers better understand community health.
BialystokAges 20–80 - NCT06406465RecruitingPhase 2
Belinostat trial for neuroendocrine cancer based on genetics
This trial tests a drug called belinostat, possibly combined with other drugs, based on your genetic makeup. It aims to find the right dose for people with a rare and aggressive neuroendocrine cancer that started outside the lungs.
Bethesda, MarylandAges 18–120 - NCT07805954RecruitingPhase 3
New targeted pills for first-line metastatic pancreatic cancer
This trial tests two new targeted pills (zoldonrasib and daraxonrasib) compared to the standard chemotherapy (gemcitabine and nab-paclitaxel) as the first treatment for metastatic pancreatic cancer with a specific KRAS G12D mutation. The new pills may specifically attack cancer cells with this mutation.
Phoenix, ArizonaAges 18 years+ - NCT07667400RecruitingPhase 1/Phase 2
Docetaxel plus SX-682 for advanced head and neck or prostate cancer
This trial studies a combination of the chemotherapy drug docetaxel and an investigational drug called SX-682 for people with certain advanced head and neck cancers or prostate cancer. The goal is to see if the combination is safe and effective.
Bethesda, MarylandAges 18–120 - NCT06904066RecruitingPhase 1
Personalized T cell therapy for blood cancers
This trial tests a treatment that takes your own immune cells, modifies them to attack cancer cells, and gives them back to you. It is for people with certain blood cancers who have specific gene changes.
Bethesda, MarylandAges 18–120 - NCT07770711Recruiting
Inositol and metformin with different diets for PCOS
This study compares two diet plans (Mediterranean and low-carb) along with the supplements inositol and metformin, to see which works better for weight and blood sugar control in women with PCOS and insulin resistance. It may help you manage PCOS symptoms and improve your body's response to insulin.
Diyarbakır, DiyarbakırAges 20–40 - NCT07493447RecruitingEarly Phase 1
Imaging dye to help see brain tumors during surgery
This study tests a special dye (panitumumab-IRDye800) that helps surgeons see brain lesions more clearly during surgery. The dye attaches to a protein on cancer cells and lights up under a special camera, which may help remove more tumor safely.
Nashville, TennesseeAges 18 years+ - NCT07460765RecruitingPhase 1
Nivolumab with a special dye for head and neck cancer surgery
This trial tests if a special dye attached to the drug nivolumab can help surgeons see cancer cells more clearly during surgery. If you have head and neck cancer and are scheduled for surgery, this study might be an option for you.
Nashville, TennesseeAges 18 years+ - NCT06179069RecruitingPhase 1
Study of ZL-1310 for small cell lung cancer
This trial tests a new drug called ZL-1310, alone or with other treatments, for people with small cell lung cancer that has spread (extensive-stage). It aims to see if ZL-1310 can help shrink tumors or slow the disease.
Duarte, CaliforniaAges 18 years+ - NCT07388524RecruitingPhase 3
Testing atezolizumab after surgery for early stage lung cancer
This trial tests if the immunotherapy drug atezolizumab can prevent early stage non-small cell lung cancer from coming back after surgery. It is for people whose tumors have high levels of a protein called PD-L1 (50% or more) and do not have certain gene changes (EGFR or ALK).
Beverly Hills, CaliforniaAges 18 years+ - NCT06430736RecruitingPhase 2
Tocilizumab before or during CAR-T therapy
This study tests whether giving tocilizumab (a drug that calms inflammation) before CAR-T cell therapy helps prevent side effects. It compares using it ahead of time versus only when needed. You may be eligible if you are scheduled for CAR-T therapy for lymphoma, leukemia, or myeloma.
Bern, Canton of BernAges 18 years+ - NCT07162506RecruitingPhase 2
Chemo-immunotherapy then surgery or radiation for esophageal cancer
This trial compares two standard treatments for esophageal cancer that has responded to initial chemo-immunotherapy: surgery to remove the tumor or radiation combined with chemotherapy. The goal is to see which approach offers better outcomes and quality of life.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07448142RecruitingPhase 2
Low-dose radiation with immunotherapy and chemo for advanced rectal cancer
This trial tests a combination of low-dose radiation, an immunotherapy drug called pucotenlimab, and chemotherapy for locally advanced rectal cancer that has not spread. The goal is to see if adding radiation helps shrink the tumor more effectively before surgery.
Guangzhou, GuanggongAges 18–75 - NCT06163430RecruitingPhase 1/Phase 2
Study of MK-4208 for chronic myeloid leukemia
This trial tests a new pill that may help people with chronic myeloid leukemia (CML) when other treatments have stopped working or caused side effects. It might offer another option for controlling the disease.
Birmingham, AlabamaAges 18 years+ - NCT07708961RecruitingPhase 2
Temozolomide with or without WSD0922-FU for EGFR-mutant glioblastoma
This trial tests whether adding a new drug, WSD0922-FU, to standard chemotherapy (temozolomide) works better than temozolomide alone for a specific type of glioblastoma that has an EGFR mutation. It is for patients who have completed radiation and temozolomide together but haven't started maintenance temozolomide yet.
Scottsdale, ArizonaAges 18 years+ - NCT07760012Recruiting
Pet scan with new tracer for solid tumors
This study uses a new imaging tracer, called 68Ga-SorB, during a PET/CT scan to look at tumors. It may help doctors see cancer more clearly. The trial is for adults with certain types of solid tumors (such as melanoma, liver, lung, breast, pancreatic, ovarian, or bile duct cancer) who need a PET/CT scan as part of their care.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07200102RecruitingPhase 1
Selinexor after CAR-T for high-risk multiple myeloma
This study tests whether taking selinexor after CAR-T cell therapy can help keep multiple myeloma from coming back. It is for people whose myeloma is high-risk or still has signs of disease after CAR-T.
St Louis, MissouriAges 18 years+ - NCT06623396RecruitingPhase 1
Mesothelin-targeted CAR T cells for esophagogastric cancer or mesothelioma
This trial tests a new treatment that uses your own immune cells (T cells) engineered to find and attack cancer cells that have a protein called mesothelin on their surface. It is for people with advanced or recurrent esophagogastric cancer (cancer of the esophagus or stomach) or malignant peritoneal mesothelioma (a rare cancer of the lining of the abdomen). The treatment involves collecting your T cells, modifying them in a lab, and then giving them back to you after a short course of chemotherapy to help them work.
Basking Ridge, New JerseyAges 18 years+ - NCT05986240RecruitingPhase 1
Danvatirsen plus venetoclax for advanced blood cancers
This trial tests a new drug called danvatirsen, first alone and then with venetoclax, for people with advanced acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that have not responded to standard treatments. The goal is to see if this combination can help shrink or control the cancer.
The Bronx, New YorkAges 18 years+ - NCT07874490RecruitingPhase 2
Osimertinib plus cyclosporine for advanced lung cancer
This study tests whether adding cyclosporine to the standard drug osimertinib can make it work better in people with advanced non-small cell lung cancer that has a specific EGFR gene change. You can join even if you haven't started treatment or have just started osimertinib within the last 3 weeks.
New York, New YorkAges 18 years+ - NCT07726342RecruitingPhase 2
Study of a new drug for advanced HER2-positive breast cancer
This study tests a new drug, SMP-656, for people with advanced HER2-positive breast cancer that has stopped responding to previous treatments. The goal is to see if it can help shrink or control the cancer.
Hefei, AnhuiAges 18 years+ - NCT07874542Recruiting
Blood test to help classify kidney masses before surgery
This study looks at whether a simple blood test can help doctors tell if a kidney mass is cancer before surgery. It aims to improve how kidney masses are classified and guide treatment decisions.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07458347RecruitingPhase 1
Study of a new drug for advanced solid tumors with a KRAS mutation
This trial tests a new pill, KST-6051, for people with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called a KRAS mutation. The goal is to see if the drug can shrink or control the cancer, and to find the best dose.
Los Angeles, CaliforniaAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,103 recruiting oncology studies from the U.S. registry right now, out of 29,584 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.